210 related articles for article (PubMed ID: 33721182)
1. Ruxolitinib in Aicardi-Goutières syndrome.
Mura E; Masnada S; Antonello C; Parazzini C; Izzo G; Garau J; Sproviero D; Cereda C; Orcesi S; Veggiotti P; Zuccotti G; Dilillo D; Penagini F; Tonduti D
Metab Brain Dis; 2021 Jun; 36(5):859-863. PubMed ID: 33721182
[TBL] [Abstract][Full Text] [Related]
2. Novel and emerging treatments for Aicardi-Goutières syndrome.
Tonduti D; Fazzi E; Badolato R; Orcesi S
Expert Rev Clin Immunol; 2020 Feb; 16(2):189-198. PubMed ID: 31855085
[No Abstract] [Full Text] [Related]
3. Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications.
Tonduti D; Izzo G; D'Arrigo S; Riva D; Moroni I; Zorzi G; Cavallera V; Pichiecchio A; Uggetti C; Veggiotti P; Orcesi S; Chiapparini L; Parazzini C
Mol Genet Metab; 2019 Apr; 126(4):489-494. PubMed ID: 30826161
[TBL] [Abstract][Full Text] [Related]
4. TREX-1 related Aicardi-Goutières syndrome improved by Janus kinase inhibitor.
Ryckmans C; Donge M; Marchèse A; Mastouri M; Thomee C; Stouffs K; Lieser SL; Scalais E
Am J Med Genet A; 2024 May; 194(5):e63510. PubMed ID: 38135344
[TBL] [Abstract][Full Text] [Related]
5. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
Yu ZX; Song HM
World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib.
Wang W; Wang W; Peng S; Gao S; Quan M; Gou L; Wang C; Sun Z; Li Z; Lian D; Song H
Pediatr Rheumatol Online J; 2023 Oct; 21(1):117. PubMed ID: 37828538
[TBL] [Abstract][Full Text] [Related]
7. Aicardi-Goutières syndrome: A monogenic type I interferonopathy.
Liu A; Ying S
Scand J Immunol; 2023 Oct; 98(4):e13314. PubMed ID: 37515439
[TBL] [Abstract][Full Text] [Related]
8. Clinical, radiological and possible pathological overlap of cystic leukoencephalopathy without megalencephaly and Aicardi-Goutières syndrome.
Tonduti D; Orcesi S; Jenkinson EM; Dorboz I; Renaldo F; Panteghini C; Rice GI; Henneke M; Livingston JH; Elmaleh M; Burglen L; Willemsen MA; Chiapparini L; Garavaglia B; Rodriguez D; Boespflug-Tanguy O; Moroni I; Crow YJ
Eur J Paediatr Neurol; 2016 Jul; 20(4):604-10. PubMed ID: 27091087
[TBL] [Abstract][Full Text] [Related]
9. Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis.
Galli J; Gavazzi F; De Simone M; Giliani S; Garau J; Valente M; Vairo D; Cattalini M; Mortilla M; Andreoli L; Badolato R; Bianchi M; Carabellese N; Cereda C; Ferraro R; Facchetti F; Fredi M; Gualdi G; Lorenzi L; Meini A; Orcesi S; Tincani A; Zanola A; Rice G; Fazzi E;
Medicine (Baltimore); 2018 Dec; 97(52):e13893. PubMed ID: 30593198
[TBL] [Abstract][Full Text] [Related]
10. Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.
Jafarpour S; Suddock J; Hawes D; Santoro JD
J Clin Immunol; 2024 Feb; 44(3):68. PubMed ID: 38381212
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome.
Zheng S; Lee PY; Wang J; Wang S; Huang Q; Huang Y; Liu Y; Zhou Q; Li T
Front Immunol; 2020; 11():985. PubMed ID: 32508843
[TBL] [Abstract][Full Text] [Related]
12. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
Front Immunol; 2022; 13():825367. PubMed ID: 35418997
[TBL] [Abstract][Full Text] [Related]
13. Late diagnosis and atypical brain imaging of Aicardi-Goutières syndrome: are we failing to diagnose Aicardi-Goutières syndrome-2?
Svingen L; Goheen M; Godfrey R; Wahl C; Baker EH; Gahl WA; Malicdan MCV; Toro C
Dev Med Child Neurol; 2017 Dec; 59(12):1307-1311. PubMed ID: 28762473
[TBL] [Abstract][Full Text] [Related]
14. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.
Frémond ML; Hully M; Fournier B; Barrois R; Lévy R; Aubart M; Castelle M; Chabalier D; Gins C; Sarda E; Al Adba B; Couderc S; D' Almeida C; Berat CM; Durrleman C; Espil C; Lambert L; Méni C; Périvier M; Pillet P; Polivka L; Schiff M; Todosi C; Uettwiller F; Lepelley A; Rice GI; Seabra L; Sanquer S; Hulin A; Pressiat C; Goldwirt L; Bondet V; Duffy D; Moshous D; Bader-Meunier B; Bodemer C; Robin-Renaldo F; Boddaert N; Blanche S; Desguerre I; Crow YJ; Neven B
J Clin Immunol; 2023 Aug; 43(6):1436-1447. PubMed ID: 37171742
[TBL] [Abstract][Full Text] [Related]
15. Opsoclonus-myoclonus in Aicardi-Goutières syndrome.
Alburaiky S; Dale RC; Crow YJ; Jones HF; Wassmer E; Melki I; Boespflug-Tanguy O; Do Cao J; Gras D; Sharpe C
Dev Med Child Neurol; 2021 Dec; 63(12):1483-1486. PubMed ID: 34155623
[TBL] [Abstract][Full Text] [Related]
16. Developmental Outcomes of Aicardi Goutières Syndrome.
Adang L; Gavazzi F; De Simone M; Fazzi E; Galli J; Koh J; Kramer-Golinkoff J; De Giorgis V; Orcesi S; Peer K; Ulrick N; Woidill S; Shults J; Vanderver A
J Child Neurol; 2020 Jan; 35(1):7-16. PubMed ID: 31559893
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutières syndrome.
Han VX; Mohammad SS; Jones HF; Bandodkar S; Crow YJ; Dale RC;
Dev Med Child Neurol; 2022 Feb; 64(2):266-271. PubMed ID: 34415581
[TBL] [Abstract][Full Text] [Related]
18. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
Vanderver A; Adang L; Gavazzi F; McDonald K; Helman G; Frank DB; Jaffe N; Yum SW; Collins A; Keller SR; Lebon P; Meritet JF; Rhee J; Takanohashi A; Armangue T; Ulrick N; Sherbini O; Koh J; Peer K; Besnier C; Scher C; Boyle K; Dubbs H; Kramer-Golinkoff J; Pizzino A; Woidill S; Shults J
N Engl J Med; 2020 Sep; 383(10):986-989. PubMed ID: 32877590
[No Abstract] [Full Text] [Related]
19. Early-Onset Aicardi-Goutières Syndrome: Magnetic Resonance Imaging (MRI) Pattern Recognition.
Vanderver A; Prust M; Kadom N; Demarest S; Crow YJ; Helman G; Orcesi S; La Piana R; Uggetti C; Wang J; Gordisch-Dressman H; van der Knaap MS; Livingston JH
J Child Neurol; 2015 Sep; 30(10):1343-8. PubMed ID: 25535058
[TBL] [Abstract][Full Text] [Related]
20. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation.
La Maestra S; Frosina G; Micale RT; D'Oria C; Garibaldi S; Daga A; Pulliero A; Izzotti A
Drug Deliv Transl Res; 2018 Oct; 8(5):1345-1354. PubMed ID: 29869293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
